 Anne Lynch
Concepts (314)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Retinopathy of Prematurity | 13 | 2024 | 128 | 6.100 |
Why?
| | Macular Degeneration | 12 | 2023 | 158 | 4.000 |
Why?
| | Birth Weight | 11 | 2024 | 494 | 2.300 |
Why?
| | Complement Factor B | 7 | 2022 | 106 | 2.290 |
Why?
| | Geographic Atrophy | 7 | 2023 | 66 | 2.150 |
Why?
| | Visual Acuity | 15 | 2024 | 319 | 1.850 |
Why?
| | Pre-Eclampsia | 8 | 2024 | 183 | 1.730 |
Why?
| | Neonatal Screening | 5 | 2022 | 161 | 1.720 |
Why?
| | Cataract | 12 | 2024 | 197 | 1.630 |
Why?
| | Gestational Age | 16 | 2024 | 857 | 1.620 |
Why?
| | Wet Macular Degeneration | 4 | 2023 | 44 | 1.610 |
Why?
| | Premature Birth | 5 | 2017 | 313 | 1.470 |
Why?
| | Retinal Drusen | 2 | 2021 | 30 | 1.400 |
Why?
| | Complement Activation | 6 | 2022 | 359 | 1.360 |
Why?
| | Phacoemulsification | 8 | 2023 | 117 | 1.210 |
Why?
| | Infant, Premature | 7 | 2024 | 540 | 1.130 |
Why?
| | Complement C3a | 2 | 2019 | 41 | 1.020 |
Why?
| | Cataract Extraction | 7 | 2024 | 93 | 0.940 |
Why?
| | Infant, Newborn | 16 | 2024 | 5707 | 0.900 |
Why?
| | Diseases in Twins | 1 | 2024 | 174 | 0.870 |
Why?
| | Diabetic Retinopathy | 5 | 2023 | 172 | 0.850 |
Why?
| | Twins | 1 | 2024 | 249 | 0.830 |
Why?
| | Risk Factors | 22 | 2024 | 9804 | 0.790 |
Why?
| | Retrospective Studies | 36 | 2024 | 14562 | 0.790 |
Why?
| | Pregnancy | 25 | 2024 | 6256 | 0.760 |
Why?
| | Fetal Membranes, Premature Rupture | 3 | 2017 | 35 | 0.760 |
Why?
| | Registries | 6 | 2024 | 1916 | 0.740 |
Why?
| | Weight Gain | 4 | 2019 | 504 | 0.700 |
Why?
| | Neurodegenerative Diseases | 1 | 2022 | 108 | 0.690 |
Why?
| | Infant, Low Birth Weight | 2 | 2017 | 134 | 0.660 |
Why?
| | Pregnancy Outcome | 7 | 2015 | 379 | 0.660 |
Why?
| | Complement Membrane Attack Complex | 1 | 2019 | 34 | 0.640 |
Why?
| | Cohort Studies | 11 | 2024 | 5400 | 0.640 |
Why?
| | Choroidal Neovascularization | 1 | 2019 | 51 | 0.620 |
Why?
| | Humans | 84 | 2024 | 129078 | 0.620 |
Why?
| | Internet | 1 | 2023 | 616 | 0.610 |
Why?
| | Female | 63 | 2024 | 68274 | 0.610 |
Why?
| | Bronchopulmonary Dysplasia | 2 | 2024 | 383 | 0.600 |
Why?
| | Algorithms | 6 | 2018 | 1626 | 0.570 |
Why?
| | Labor, Induced | 2 | 2017 | 31 | 0.570 |
Why?
| | Abnormalities, Multiple | 1 | 2019 | 178 | 0.570 |
Why?
| | Diagnostic Techniques, Ophthalmological | 2 | 2018 | 38 | 0.550 |
Why?
| | Labor, Obstetric | 1 | 2017 | 55 | 0.540 |
Why?
| | Retinal Detachment | 3 | 2023 | 57 | 0.540 |
Why?
| | Colorado | 11 | 2024 | 4445 | 0.540 |
Why?
| | Blood Proteins | 2 | 2015 | 233 | 0.530 |
Why?
| | Intraocular Pressure | 5 | 2024 | 297 | 0.510 |
Why?
| | Pregnancy Trimester, First | 2 | 2015 | 133 | 0.500 |
Why?
| | Refraction, Ocular | 4 | 2024 | 36 | 0.480 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2017 | 308 | 0.470 |
Why?
| | Infant, Very Low Birth Weight | 4 | 2019 | 68 | 0.440 |
Why?
| | Infant | 12 | 2022 | 8997 | 0.440 |
Why?
| | Placenta | 2 | 2018 | 706 | 0.440 |
Why?
| | Inflammation | 4 | 2023 | 2696 | 0.430 |
Why?
| | Photorefractive Keratectomy | 2 | 2024 | 19 | 0.420 |
Why?
| | Intraoperative Complications | 4 | 2022 | 134 | 0.420 |
Why?
| | Keratomileusis, Laser In Situ | 2 | 2024 | 22 | 0.420 |
Why?
| | Myopia | 3 | 2024 | 48 | 0.410 |
Why?
| | Influenza A Virus, H1N1 Subtype | 2 | 2012 | 145 | 0.410 |
Why?
| | Research Design | 1 | 2019 | 1039 | 0.410 |
Why?
| | Tomography, Optical Coherence | 4 | 2023 | 182 | 0.400 |
Why?
| | Male | 38 | 2024 | 63248 | 0.390 |
Why?
| | Vitrectomy | 3 | 2021 | 64 | 0.380 |
Why?
| | Logistic Models | 9 | 2024 | 1966 | 0.380 |
Why?
| | Cesarean Section | 3 | 2011 | 180 | 0.380 |
Why?
| | Biomarkers | 8 | 2023 | 3878 | 0.380 |
Why?
| | Keratotomy, Radial | 2 | 2022 | 9 | 0.380 |
Why?
| | Lens Implantation, Intraocular | 4 | 2022 | 59 | 0.370 |
Why?
| | Aged | 21 | 2024 | 22068 | 0.370 |
Why?
| | Body Mass Index | 4 | 2014 | 2250 | 0.370 |
Why?
| | Odds Ratio | 5 | 2019 | 1021 | 0.370 |
Why?
| | Retinal Diseases | 2 | 2023 | 86 | 0.370 |
Why?
| | Pregnancy Complications | 3 | 2010 | 487 | 0.360 |
Why?
| | Pregnancy Complications, Infectious | 2 | 2012 | 334 | 0.350 |
Why?
| | Complement Activating Enzymes | 1 | 2010 | 3 | 0.340 |
Why?
| | Pregnant Women | 1 | 2011 | 118 | 0.340 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2010 | 70 | 0.330 |
Why?
| | Influenza Vaccines | 2 | 2012 | 544 | 0.320 |
Why?
| | Aged, 80 and over | 11 | 2023 | 7063 | 0.310 |
Why?
| | Immunologic Factors | 2 | 2022 | 227 | 0.310 |
Why?
| | Obesity | 3 | 2014 | 2847 | 0.300 |
Why?
| | Influenza, Human | 2 | 2012 | 603 | 0.300 |
Why?
| | Complement Pathway, Alternative | 2 | 2013 | 114 | 0.300 |
Why?
| | Prospective Studies | 13 | 2023 | 7070 | 0.290 |
Why?
| | Follow-Up Studies | 10 | 2024 | 4927 | 0.290 |
Why?
| | Adult | 24 | 2024 | 35423 | 0.290 |
Why?
| | Receptors, Cell Surface | 1 | 2010 | 379 | 0.290 |
Why?
| | Antibodies, Antiphospholipid | 3 | 1999 | 27 | 0.290 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2019 | 822 | 0.280 |
Why?
| | Sensitivity and Specificity | 3 | 2017 | 1842 | 0.280 |
Why?
| | Lenses, Intraocular | 3 | 2022 | 43 | 0.280 |
Why?
| | Antigens, CD | 1 | 2010 | 480 | 0.280 |
Why?
| | Lasers, Excimer | 2 | 2024 | 29 | 0.270 |
Why?
| | Case-Control Studies | 7 | 2022 | 3336 | 0.250 |
Why?
| | Fluorescein Angiography | 3 | 2023 | 139 | 0.250 |
Why?
| | Chemokine CCL5 | 2 | 2023 | 44 | 0.250 |
Why?
| | Glaucoma | 2 | 2018 | 217 | 0.240 |
Why?
| | Incidence | 4 | 2022 | 2635 | 0.240 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2011 | 1264 | 0.230 |
Why?
| | Diabetes Mellitus | 2 | 2023 | 991 | 0.230 |
Why?
| | Postoperative Complications | 5 | 2023 | 2497 | 0.220 |
Why?
| | Membrane Proteins | 1 | 2010 | 1102 | 0.220 |
Why?
| | Vitreous Body | 2 | 2022 | 104 | 0.210 |
Why?
| | Hypertension, Pregnancy-Induced | 1 | 2024 | 67 | 0.210 |
Why?
| | Methylprednisolone | 1 | 2023 | 83 | 0.210 |
Why?
| | Optic Neuritis | 1 | 2023 | 38 | 0.210 |
Why?
| | Vision, Low | 1 | 2022 | 16 | 0.200 |
Why?
| | Angiogenesis Inhibitors | 2 | 2023 | 222 | 0.200 |
Why?
| | Vaccination | 1 | 2011 | 1351 | 0.200 |
Why?
| | Multivariate Analysis | 2 | 2019 | 1504 | 0.190 |
Why?
| | Retinal Perforations | 1 | 2022 | 14 | 0.190 |
Why?
| | Proteomics | 2 | 2020 | 988 | 0.190 |
Why?
| | Posterior Capsulotomy | 1 | 2021 | 7 | 0.190 |
Why?
| | Posterior Capsule of the Lens | 1 | 2021 | 10 | 0.190 |
Why?
| | Capsule Opacification | 1 | 2021 | 20 | 0.190 |
Why?
| | Retinal Ganglion Cells | 1 | 2022 | 95 | 0.190 |
Why?
| | Lasers, Solid-State | 1 | 2021 | 23 | 0.180 |
Why?
| | National Eye Institute (U.S.) | 1 | 2020 | 6 | 0.180 |
Why?
| | Complement System Proteins | 2 | 2022 | 307 | 0.180 |
Why?
| | Aberrometry | 1 | 2020 | 9 | 0.180 |
Why?
| | Eye Banks | 1 | 2020 | 6 | 0.180 |
Why?
| | Corneal Transplantation | 1 | 2020 | 13 | 0.180 |
Why?
| | Posterior Capsular Rupture, Ocular | 1 | 2020 | 6 | 0.180 |
Why?
| | Trabeculectomy | 2 | 2018 | 73 | 0.180 |
Why?
| | Abortion, Spontaneous | 2 | 1999 | 97 | 0.180 |
Why?
| | Optics and Photonics | 1 | 2020 | 41 | 0.180 |
Why?
| | Risk Assessment | 3 | 2019 | 3290 | 0.170 |
Why?
| | Quality of Life | 5 | 2023 | 2711 | 0.170 |
Why?
| | Oculomotor Muscles | 1 | 2020 | 39 | 0.170 |
Why?
| | Strabismus | 1 | 2020 | 29 | 0.170 |
Why?
| | Dementia | 1 | 2023 | 230 | 0.170 |
Why?
| | Scleral Buckling | 1 | 2019 | 18 | 0.170 |
Why?
| | Retinal Neovascularization | 1 | 2019 | 22 | 0.170 |
Why?
| | Macula Lutea | 1 | 2019 | 18 | 0.170 |
Why?
| | Hepatitis C | 1 | 2022 | 234 | 0.170 |
Why?
| | Ophthalmologic Surgical Procedures | 1 | 2020 | 56 | 0.170 |
Why?
| | Middle Aged | 16 | 2024 | 31024 | 0.170 |
Why?
| | Laser Therapy | 1 | 2021 | 127 | 0.160 |
Why?
| | Surveys and Questionnaires | 6 | 2022 | 5365 | 0.160 |
Why?
| | United States | 8 | 2020 | 13992 | 0.160 |
Why?
| | Homosexuality, Male | 1 | 2020 | 172 | 0.160 |
Why?
| | Uveitis, Posterior | 1 | 2019 | 12 | 0.160 |
Why?
| | Estrogen Replacement Therapy | 1 | 2019 | 141 | 0.150 |
Why?
| | Dermatitis, Atopic | 1 | 2022 | 335 | 0.150 |
Why?
| | Pilocarpine | 1 | 2018 | 16 | 0.150 |
Why?
| | Immunity, Maternally-Acquired | 1 | 2018 | 18 | 0.150 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 1999 | 80 | 0.150 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2023 | 2421 | 0.150 |
Why?
| | Ophthalmic Solutions | 1 | 2018 | 74 | 0.150 |
Why?
| | Glaucoma, Angle-Closure | 1 | 2018 | 16 | 0.150 |
Why?
| | Disease Progression | 3 | 2022 | 2607 | 0.150 |
Why?
| | Ocular Hypertension | 1 | 2018 | 62 | 0.140 |
Why?
| | Metformin | 1 | 2021 | 307 | 0.140 |
Why?
| | Trabecular Meshwork | 1 | 2018 | 79 | 0.140 |
Why?
| | Anti-Inflammatory Agents | 1 | 2021 | 468 | 0.140 |
Why?
| | Laser Coagulation | 1 | 2017 | 57 | 0.140 |
Why?
| | Adrenergic alpha-1 Receptor Antagonists | 1 | 2016 | 19 | 0.140 |
Why?
| | Glycoproteins | 1 | 1999 | 340 | 0.140 |
Why?
| | Parity | 1 | 2017 | 120 | 0.130 |
Why?
| | Glaucoma, Open-Angle | 1 | 2018 | 103 | 0.130 |
Why?
| | Automobile Driving | 1 | 2018 | 142 | 0.130 |
Why?
| | Tonometry, Ocular | 3 | 2024 | 88 | 0.130 |
Why?
| | Infant, Extremely Low Birth Weight | 1 | 2016 | 20 | 0.130 |
Why?
| | Fetus | 2 | 2018 | 764 | 0.130 |
Why?
| | Time Factors | 4 | 2021 | 6579 | 0.130 |
Why?
| | Young Adult | 8 | 2019 | 12310 | 0.130 |
Why?
| | Recovery of Function | 1 | 2019 | 642 | 0.120 |
Why?
| | Risk | 1 | 2018 | 867 | 0.120 |
Why?
| | Time-to-Pregnancy | 1 | 2015 | 5 | 0.120 |
Why?
| | Severity of Illness Index | 2 | 2024 | 2768 | 0.120 |
Why?
| | Proteins | 1 | 2020 | 945 | 0.110 |
Why?
| | Phenotype | 2 | 2022 | 3062 | 0.110 |
Why?
| | Mothers | 2 | 2018 | 723 | 0.110 |
Why?
| | Self Report | 1 | 2018 | 797 | 0.110 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2017 | 226 | 0.110 |
Why?
| | Obstetric Labor, Premature | 1 | 2013 | 35 | 0.110 |
Why?
| | Cervical Ripening | 1 | 2013 | 9 | 0.100 |
Why?
| | Sulfonamides | 1 | 2016 | 494 | 0.100 |
Why?
| | Uterine Hemorrhage | 1 | 2013 | 34 | 0.100 |
Why?
| | Cervix Uteri | 1 | 2013 | 50 | 0.100 |
Why?
| | Treatment Outcome | 6 | 2024 | 10256 | 0.100 |
Why?
| | Models, Statistical | 1 | 2016 | 627 | 0.100 |
Why?
| | Pulmonary Fibrosis | 2 | 2008 | 381 | 0.100 |
Why?
| | Aspirin | 1 | 2015 | 379 | 0.090 |
Why?
| | Axial Length, Eye | 2 | 2024 | 15 | 0.090 |
Why?
| | Tertiary Healthcare | 2 | 2022 | 30 | 0.090 |
Why?
| | Infant, Small for Gestational Age | 1 | 2012 | 83 | 0.090 |
Why?
| | Cross-Sectional Studies | 4 | 2020 | 5036 | 0.090 |
Why?
| | Fetal Blood | 1 | 2013 | 315 | 0.090 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2015 | 453 | 0.090 |
Why?
| | Autoantibodies | 1 | 1999 | 1464 | 0.090 |
Why?
| | Endoglin | 1 | 2010 | 19 | 0.090 |
Why?
| | Hypertension | 1 | 1999 | 1237 | 0.080 |
Why?
| | Adiposity | 1 | 2014 | 505 | 0.080 |
Why?
| | Cesarean Section, Repeat | 1 | 2009 | 11 | 0.080 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2023 | 529 | 0.080 |
Why?
| | Intensive Care, Neonatal | 1 | 2009 | 41 | 0.080 |
Why?
| | Postoperative Period | 2 | 2020 | 320 | 0.080 |
Why?
| | Placental Insufficiency | 1 | 2010 | 111 | 0.080 |
Why?
| | Child | 4 | 2022 | 20860 | 0.080 |
Why?
| | Models, Biological | 1 | 2016 | 1704 | 0.080 |
Why?
| | Academic Medical Centers | 2 | 2022 | 473 | 0.080 |
Why?
| | Seasons | 1 | 2011 | 502 | 0.070 |
Why?
| | Health Status Disparities | 1 | 2011 | 242 | 0.070 |
Why?
| | Pregnancy Trimester, Third | 1 | 2008 | 105 | 0.070 |
Why?
| | Elective Surgical Procedures | 1 | 2009 | 164 | 0.070 |
Why?
| | Heart Rate | 1 | 2012 | 808 | 0.070 |
Why?
| | ROC Curve | 2 | 2019 | 501 | 0.070 |
Why?
| | Resuscitation | 1 | 2009 | 244 | 0.070 |
Why?
| | Patient Compliance | 1 | 2011 | 563 | 0.070 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2023 | 3604 | 0.070 |
Why?
| | Glyburide | 1 | 2006 | 35 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 2 | 2008 | 2530 | 0.060 |
Why?
| | Predictive Value of Tests | 2 | 2008 | 1968 | 0.060 |
Why?
| | Hypoglycemic Agents | 2 | 2021 | 1208 | 0.060 |
Why?
| | Ultrasonography, Doppler | 1 | 2005 | 118 | 0.060 |
Why?
| | Blood Pressure | 1 | 2012 | 1746 | 0.060 |
Why?
| | Urban Health | 1 | 2004 | 78 | 0.060 |
Why?
| | Papanicolaou Test | 1 | 2004 | 43 | 0.060 |
Why?
| | Vaginal Smears | 1 | 2004 | 56 | 0.060 |
Why?
| | Fetal Growth Retardation | 2 | 2012 | 542 | 0.060 |
Why?
| | Contraceptives, Oral, Combined | 1 | 2004 | 17 | 0.060 |
Why?
| | Refractive Errors | 1 | 2024 | 18 | 0.060 |
Why?
| | Uterus | 1 | 2005 | 204 | 0.060 |
Why?
| | Prevalence | 2 | 2024 | 2541 | 0.060 |
Why?
| | Ovarian Follicle | 1 | 2004 | 63 | 0.050 |
Why?
| | Hospitals, County | 1 | 2023 | 10 | 0.050 |
Why?
| | Length of Stay | 1 | 2009 | 1128 | 0.050 |
Why?
| | Double-Blind Method | 4 | 2015 | 1864 | 0.050 |
Why?
| | Neuroprotection | 1 | 2023 | 33 | 0.050 |
Why?
| | Practice Guidelines as Topic | 1 | 2011 | 1526 | 0.050 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2023 | 132 | 0.050 |
Why?
| | Interleukin-4 | 1 | 2023 | 214 | 0.050 |
Why?
| | Complement Factor I | 1 | 2022 | 12 | 0.050 |
Why?
| | Aqueous Humor | 1 | 2022 | 33 | 0.050 |
Why?
| | Pandemics | 1 | 2011 | 1516 | 0.050 |
Why?
| | Alanine Transaminase | 1 | 2022 | 147 | 0.050 |
Why?
| | Diabetes, Gestational | 1 | 2006 | 306 | 0.050 |
Why?
| | Cornea | 1 | 2022 | 109 | 0.050 |
Why?
| | Albumins | 1 | 2022 | 102 | 0.050 |
Why?
| | Vision Disorders | 1 | 2022 | 133 | 0.050 |
Why?
| | Fibrinogen | 1 | 2022 | 159 | 0.050 |
Why?
| | Intraoperative Period | 1 | 2020 | 53 | 0.040 |
Why?
| | Hepacivirus | 1 | 2022 | 235 | 0.040 |
Why?
| | Sickness Impact Profile | 1 | 2020 | 55 | 0.040 |
Why?
| | Myotomy | 1 | 2020 | 9 | 0.040 |
Why?
| | Vision, Binocular | 1 | 2020 | 17 | 0.040 |
Why?
| | Intravitreal Injections | 1 | 2020 | 55 | 0.040 |
Why?
| | Eye Movements | 1 | 2020 | 58 | 0.040 |
Why?
| | Growth Charts | 1 | 2019 | 14 | 0.040 |
Why?
| | Protective Factors | 1 | 2019 | 91 | 0.040 |
Why?
| | Adolescent | 5 | 2020 | 20241 | 0.040 |
Why?
| | HIV | 1 | 2020 | 223 | 0.040 |
Why?
| | Canada | 1 | 2020 | 355 | 0.040 |
Why?
| | beta 2-Glycoprotein I | 1 | 1999 | 4 | 0.040 |
Why?
| | Antibodies, Anticardiolipin | 1 | 1999 | 8 | 0.040 |
Why?
| | Remission, Spontaneous | 1 | 2019 | 38 | 0.040 |
Why?
| | Pulmonary Gas Exchange | 1 | 1999 | 119 | 0.040 |
Why?
| | Anthropometry | 1 | 2019 | 205 | 0.040 |
Why?
| | Area Under Curve | 1 | 2019 | 286 | 0.040 |
Why?
| | Positive-Pressure Respiration | 1 | 1999 | 75 | 0.040 |
Why?
| | Phosphatidylserines | 1 | 1999 | 89 | 0.040 |
Why?
| | Corneal Pachymetry | 1 | 2018 | 14 | 0.040 |
Why?
| | Exfoliation Syndrome | 1 | 2018 | 10 | 0.040 |
Why?
| | Pseudophakia | 1 | 2018 | 11 | 0.040 |
Why?
| | Patient Acceptance of Health Care | 1 | 2004 | 764 | 0.040 |
Why?
| | Child, Preschool | 3 | 2022 | 10462 | 0.040 |
Why?
| | Confidence Intervals | 1 | 1999 | 318 | 0.040 |
Why?
| | Family | 1 | 2022 | 651 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 1999 | 268 | 0.040 |
Why?
| | Physical Examination | 1 | 2019 | 238 | 0.040 |
Why?
| | Bronchodilator Agents | 1 | 1999 | 252 | 0.030 |
Why?
| | North America | 1 | 2018 | 289 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2022 | 731 | 0.030 |
Why?
| | Sex Characteristics | 1 | 2022 | 724 | 0.030 |
Why?
| | Equipment Design | 1 | 2018 | 523 | 0.030 |
Why?
| | Transcriptome | 1 | 2022 | 875 | 0.030 |
Why?
| | Mental Health | 1 | 2022 | 677 | 0.030 |
Why?
| | Interferon-beta | 2 | 2008 | 88 | 0.030 |
Why?
| | Respiratory Insufficiency | 1 | 1999 | 317 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 1999 | 837 | 0.030 |
Why?
| | Plethysmography | 1 | 2014 | 109 | 0.030 |
Why?
| | Apgar Score | 1 | 1994 | 18 | 0.030 |
Why?
| | Respiratory Function Tests | 2 | 2008 | 596 | 0.030 |
Why?
| | Nitric Oxide | 1 | 1999 | 892 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2022 | 1913 | 0.030 |
Why?
| | Mice | 1 | 2010 | 16583 | 0.030 |
Why?
| | Linear Models | 1 | 2014 | 818 | 0.020 |
Why?
| | Organ Size | 1 | 2013 | 446 | 0.020 |
Why?
| | Treatment Failure | 2 | 2006 | 347 | 0.020 |
Why?
| | Maternal-Fetal Exchange | 1 | 2012 | 159 | 0.020 |
Why?
| | Adipose Tissue | 1 | 2014 | 588 | 0.020 |
Why?
| | Body Composition | 1 | 2014 | 654 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2014 | 1192 | 0.020 |
Why?
| | Animals | 1 | 2010 | 34708 | 0.020 |
Why?
| | Antibodies, Viral | 1 | 2012 | 599 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2008 | 513 | 0.020 |
Why?
| | Fetal Macrosomia | 1 | 2006 | 60 | 0.020 |
Why?
| | Rheology | 1 | 2005 | 91 | 0.010 |
Why?
| | Chicago | 1 | 2004 | 51 | 0.010 |
Why?
| | Survival Analysis | 1 | 2008 | 1283 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 2008 | 1221 | 0.010 |
Why?
| | Ethinyl Estradiol | 1 | 2004 | 17 | 0.010 |
Why?
| | Levonorgestrel | 1 | 2004 | 34 | 0.010 |
Why?
| | Desogestrel | 1 | 2004 | 46 | 0.010 |
Why?
| | Ultrasonography, Prenatal | 1 | 2005 | 266 | 0.010 |
Why?
| | Menstrual Cycle | 1 | 2004 | 124 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 2004 | 760 | 0.010 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2004 | 233 | 0.010 |
Why?
| | Women's Health | 1 | 2004 | 361 | 0.010 |
Why?
| | Regression Analysis | 1 | 2003 | 987 | 0.010 |
Why?
| | Administration, Inhalation | 1 | 1999 | 675 | 0.010 |
Why?
| | Oxygen | 1 | 1999 | 913 | 0.010 |
Why?
| | Hypoxia | 1 | 1999 | 1071 | 0.010 |
Why?
|
|
Lynch's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|